A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib

NCT04772612 | Completed Phase 1 FDA Drug

• 1 other identifier: 516-012
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 5

Brief Summary

A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on the Single-Dose Pharmacokinetics of Sitravatinib

Conditions

Hepatic Impairment

Outcome Measures

Primary Outcomes (8)

• Pharmacokinetics - AUClast (sitravatinib)

  AUC from time zero to the last measured time point

  9 days

• Pharmacokinetics - Tmax (sitravatinib)

  Time to reach maximum observed plasma concentration

  9 days

• Pharmacokinetics - AUC∞ (sitravatinib)

  Area under the plasma concentration-time curve from time zero extrapolated to infinity moderate, or severe hepatic impairment compared to control subjects with normal hepatic function

  9 days

• Pharmacokinetics - Cmax (sitravatinib)

  Maximum observed plasma concentration

  9 days

• Pharmacokinetics - t1/2 (sitravatinib)

  Terminal elimination half-life

  9 days

• Pharmacokinetics - CL/F (sitravatinib)

  Apparent total plasma clearance when dosed orally

  9 days

• Pharmacokinetics - Vz/F (sitravatinib)

  Apparent volume of distribution when dosed orally

  9 days

• Pharmacokinetics - fu (sitravatinib)

  Unbound fraction

  days 1 - 4

Secondary Outcomes (1)

• Adverse Events (AEs)

  From the time the ICF is signed until 14 ± 2 days after the last dose of sitravatinib treatment

Study Arms (4)

Sitravatinib in healthy subjects

EXPERIMENTAL

Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in healthy subjects.

Drug: sitravatinib

Sitravatinib in subjects with mild hepatic impairment

EXPERIMENTAL

Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with mild hepatic impairment

Drug: sitravatinib

Sitravatinib in subjects with moderate hepatic impairment

EXPERIMENTAL

Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with moderate hepatic impairment

Drug: sitravatinib

Sitravatinib in subjects with severe hepatic impairment

EXPERIMENTAL

Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with severe hepatic impairment

Drug: sitravatinib

Interventions

sitravatinib DRUG

sitravatinib

Sitravatinib in healthy subjects; Sitravatinib in subjects with mild hepatic impairment; Sitravatinib in subjects with moderate hepatic impairment; Sitravatinib in subjects with severe hepatic impairment

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males or females, of any race, between 18 and 75 years of age, inclusive, at screening.
• Body mass index between 18.0 and 40.0 kg/m2, inclusive, at screening.
• Females of childbearing potential will not be pregnant or lactating and must have a negative result on an approved pregnancy test at screening and check-in. Females of childbearing potential must agree to use contraception by a method of proven reliability (including abstinence) as detailed in the protocol.
• Male subjects must agree to use contraception as detailed in the protocol.
• Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
• Participants with normal hepatic function must also satisfy the following criteria:
• \- Participants with normal hepatic function must be in good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, or clinical laboratory evaluations at screening and check-in as assessed by the investigator.
• Participants with hepatic impairment must also satisfy the following criteria:
• \- Participants must meet the criteria for mild, moderate, or severe hepatic impairment based on Child Pugh (CP) score and classification as detailed in the protocol. Hepatically-impaired participants will be assigned to groups according to CP scores calculated at screening; CP scores will be recalculated at check-in to confirm that subjects do not have significant changes in status to ensure subject safety for the study, as determined by the investigator and medical monitor.

You may not qualify if:

• Significant history or clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator.
• History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications (Cholecystectomy is not allowed.).
• Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days or 5 half-lives prior to dosing, whichever is longer.
• Participants who, in the opinion of the investigator, should not participate in this study.
• Participants with normal hepatic function will be excluded from the study if any of the following criteria are applicable:
• Significant history or clinical manifestation of any hepatic disease, as determined by lab abnormalities: AST, ALT, alkaline phosphatase, or alpha-fetoprotein \>1 × upper limit of normal or as deemed clinically significant by the investigator.
• Participant has creatinine clearance \<80 mL/minute as calculated by using the Cockcroft-Gault equation.
• Use or intend to use any prescription medications/products within 14 days prior to dosing, unless deemed acceptable by the investigator, medical monitor, and sponsor.
• Participants with hepatic impairment will be excluded from the study if any of the following criteria are applicable:
• Ventricular dysfunction or history of risk factors for Torsades de Pointes (eg, unexplained syncope, known long QT syndrome, heart failure, and cardiomyopathy).
• Participant has had a change in disease status within 90 days prior to the study drug administration on Day 1, as documented by the subject's medical history, deemed clinically significant by the investigator.
• Participant has required a new medication or a change in medication dose within 2 weeks before dosing with sitravatinib.
• Participant has a current functioning organ transplant or is waiting for an organ transplant.
• History of unstable diabetes mellitus as evidenced by hemoglobin A1c ≥9% at screening.
• Uncontrolled arterial hypertension (\> 150 mm Hg systolic or \>100 mm Hg diastolic) on multiple observations despite standard of care treatment.

Sponsors & Collaborators

• Mirati Therapeutics Inc.: lead

Study Sites (5)

Orange County Research Center

Tustin, California, 92780, United States

Location

Clinical Pharmacology of Miami

Miami, Florida, 33014, United States

Location

Orlando Clinical Research Center

Orlando, Florida, 32809, United States

Location

Nucleus Network

Saint Paul, Minnesota, 55114, United States

Location

Texas Liver Institute

Austin, Texas, 78757, United States

Location

MeSH Terms

Interventions

sitravatinib

Study Officials

• Curtis Chin, MD

  Mirati Therapeutics

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 23, 2021
• First Posted: February 26, 2021
• Study Start: March 12, 2021
• Primary Completion: July 13, 2022
• Study Completion: April 13, 2023
• Last Updated: October 23, 2023

Record last verified: 2023-10

Locations

US (5)